Capricor Therapeutics
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10865 Road to the Cure Ste 150, San Dieg...Phone Number
(858) 727-1755Website
www.capricor.comRevenue
$11.1 MillionStock Symbol
CAPRIndustry
About Capricor Therapeutics
Capricor Therapeutics Org Chart
Is Capricor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Capricor Therapeutics had a recent Job posting/layoffs
Capricor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Capricor Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Capricor Therapeutics has new funding data
Product Launch: Get notified when Capricor Therapeutics launches new products
Check if Capricor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Capricor Therapeutics
Check out if Capricor Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Capricor Therapeutics
Find 2 more new buyers
Compare Similar Companies to Capricor Therapeutics
Compare insights from companies similar to Capricor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Capricor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Capricor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Capricor Therapeutics.
Capricor Therapeutics financials insights
Gather financial insights about Capricor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$150K
Private Equity
$35M
Capricor Therapeutics Tech Stack
A closer look at the technologies used by Capricor Therapeutics
Most Recent Scoops
Capricor Therapeutics News & Media
Capricor Therapeutics, Inc. Investor Alert - Robbins LLP Reminds CAPR Investors with Significant Losses of the Opportunity to Lead the Class Action Lawsuit Against the Company
SAN DIEGO, Aug. 24, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026...Levi & Korsinsky Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR
Wall Street's view of Capricor Therapeutics reversed within hours after FDA briefing documents allegedly exposed unagreed changes to the HOPE-3 statistical analysis plan, with analysts questioning data integrity as CAPR shares fell 78.7% Wall Street's view of Capricor Therapeutics reversed within hours after FDA briefing documents allegedly exposed unagreed changes to the HOPE-3 statistical analysis plan, with analysts questioning data integrity as CAPR shares fell 78.7%CLASS ACTION NOTICE: Berger Montague Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Inquire About a Securities Fraud Class Action
PHILADELPHIA, Aug. 24, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor" or the "Company") on behalf of investors who purchased or acquired Capricor securities during the...Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –
Top Business Services Companies
Frequently Asked Questions Regarding Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative... Read More
